Category: Penny Stock NewsSort
Low Carbon Technologies International, Inc. (LWCTF) to Release 6-Month YTD Financials Next Week or Sooner
Shortly before the closing bell today, Low Carbon Technologies International announced that it will be reporting year-to-date financials on or before May 7th, 2013. Expectations from investors are high as last month the company reported YTD revenues have already exceeded entire revenues from fiscal 2012.
The Guitammer Company (GTMM) Partner Expands Business Relationship, Wins Prestigious “ET NOW Leaders of Tomorrow Awards 2012″
The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker®-brand low frequency audio transducers, was happy to announce today that its Indian partner, Recliners India Pvt. Ltd., a leading manufacturer of home theater seating solutions in India, won the “ET NOW Leaders of Tomorrow Awards 2012 in the Home Décor & Handicrafts Category.”
Loans4Less.com, Inc. (LFLS) Offers an Important Home Buyer Starting Point
In a recent Washington Post article by Robert McCartney (http://dtg.fm/43iJ), the importance of careful shopping when it comes to real estate transactions was made clear. The article points to lawsuits currently being brought against individuals accused of arranging kickbacks for steering business to specific companies, arrangements that homebuyers can end up paying for in the form of higher title, mortgage, or other fees.
The Aristocrat Group Corp. (ASCC) Wins Patent Approval for New Vodka Brand – Name Debut on the Horizon
VentriPoint Diagnostics Ltd. (VPTDF) Receives Expanded License from Health Canada
Today, VentriPoint Diagnostics reported receiving an expanded license from Health Canada that allows the company to sell the VMS™ heart analysis system for clinical use in Canada. The expansion was for the NRV™ application for the analysis of 2-D ultrasound images for patients with non-specific heart disease. The NRV™ application will enable healthcare providers to rapidly and accurately assess the status of the right ventricle in all patients that do not have significant congenital heart defects or pulmonary hypertension, yet may have a variety of other conditions.
Advaxis, Inc. (ADXS) Encouraged by Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study
Advaxis, a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases, today told investors of encouraging preliminary data from the Phase 1 dose escalation study evaluating the safety of ADXS-cHER2 in companion dogs with Her2/neu overexpressing canine osteosarcoma being conducted at the University of Pennsylvania School of Veterinary Medicine.
Cardium Therapeutics, Inc. (CXM) Looks to Future with Three-Stage Growth Plan
Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in several markets, much like a rocket with multiple stages timed for continuous acceleration.
Low Carbon Technologies International is a U.S. based diversified clean-tech holding company focused on the clean-tech, construction, energy, environmental, mining, and real estate sectors. The company’s primary focus is on generating consistent shareholder growth by minimizing expenses and increasing asset values through leveraged acquisitions.
Soul and Vibe Interactive, Inc. (SOUL) Founder Has Firm Foothold in Prosperous Video Game Industry
The U.S. entertainment industry is aggressive in nature, comprised of market players producing a vast and diverse offering of experiences and simulations that cater to every imaginable consumer demographic. The gaming segment of the industry has achieved exceptional performance throughout its history, and isn’t showing any signs that it will slow its pace.
VentriPoint Diagnostics, Inc. (VPTDF) Reports FDA Response to 510 (k) Submission for Pulmonary Arterial Hypertension
VentriPoint Diagnostics, creator of the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function, announced that the U.S. Food and Drug Administration (FDA) responded to its Pulmonary Arterial Hypertension (PAH) 510(k) submission with a short list of suggestions, clarifications and requests for additional information.
“We are very pleased the FDA has reviewed our submission so expeditiously and we now have a small number of modifications to the filing to prepare,” said, Dr. George Adams, CEO of VentriPoint.